Malignancy After Heart Transplantation Under Everolimus Versus Mycophenolate Mofetil Immunosuppression

• DOI: 10.1016/j.transproceed.2015.12.071
• Publication Date: 2016-05-24T23:36:42Z
• Authors: Y.-J. Wang; N.-H. Chi; N.-K. Chou; S.-C. Huang; C.-H. Wang; I.-H. Wu; H.-Y. Yu; Y.-S. Chen; C.-I. Tsao; C.-T. Shun; J.-T. Tsai; S.-S. Wang
• Keywords: Adult; Immunosuppression Therapy; Male; Adolescent; Incidence; Lymphoma, Non-Hodgkin; Infant; Kaplan-Meier Estimate; Middle Aged; Mycophenolic Acid; 3. Good health; 03 medical and health sciences; 0302 clinical medicine; Child, Preschool; Animals; Heart Transplantation; Humans; Female; Everolimus; Child; Immunosuppressive Agents; Aged; Follow-Up Studies

With advances in immunosuppressive therapy, heart transplantation is currently recommended as the only established surgical treatment for refractory heart failure. However, chronic immunosuppression increases the risk for malignancy. Everolimus (EVR) is a potent mammalian target of rapamycin inhibitor that is used after transplantation and to treat advanced malignancies, as we have done in Taiwan after heart transplantation since 2004. Mycophenolate mofetil (MMF) and EVR are frequently used as cell-cycle inhibitors to optimize post-transplantation outcomes.We retrospectively analyzed the characteristics and outcomes of 454 patients who received either MMF (n = 232) or EVR (n = 222) after heart transplantation at the National Taiwan University Hospital from March 1, 1990, to March 1, 2015. Patient characteristics and Kaplan-Meier survival curves were compared between groups.During a median follow-up of 69.2 months, malignancy was diagnosed in 27 patients receiving MMF (n = 23) or EVR (n = 4). There was a significant difference in malignancy risk between groups (9.91% vs 1.80%, P = .001). The most common malignancies were non-Hodgkin lymphoma, skin cancers, and lung squamous cell carcinoma. The 2-year overall survival after malignancy was 50% in the EVR group and 47% in the MMF group (P = .745).EVR treatment after heart transplant is associated with a lower risk of malignancy than is MMF treatment. The 2-year survival rate after malignancy was similar between EVR and MMF groups.